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Abstract: In uropathogenic Escherichia coli, mannose-specific adhesion is mediated by the FimH adhesin located at the tip of type 1 fimbriae. 
Novel mannosylated N-aryl substituted 3-hydroxypyridin-4ones with meta substituents on the aryl part of the molecule were prepared, and 
their inhibitory properties towards the adhesion of E. coli to guinea pig erythrocytes explored using the hemagglutination assay. These results 
were compared with inhibitory potencies of analogous para derivatives. The assays revealed greater preference of FimH towards para substi-
tuted compounds in general, with p-nitro and p-methoxy substituted substrates being much more effective then the hydrophobic p-methyl 
compound. When substituents are in meta position the positive affect on the binding of compounds in the FimH binding site was observed 
with all compounds tested but the structure with an alkyl group was shown to be the most effective one. This study provides guidelines for the 
rational design of novel, more effective series of FimH antagonists. 
 





esearch in the field of glycobiology has shown that the 
process of molecular recognition involving bacterial 
cell-surface proteins called lectins and complementary 
carbohydrates is of essentaial importance in many bio-
logical processes.1,2 Adhesion of pathogenic organisms to 
host tissues is the initiation of the majority of infectious 
diseases and is often mediated by lectins present on the 
surface of infectious organisms which then combine with 
complementary sugars on the host surface.3 Therefore, 
the concept of anti-adhesion therapy of microbial diseases 
based on blocking or inhibiting lectins by suitable 
carbohydrates has gradually emerged.4–8 This concept 
seems to be an attractive and promising alternative to 
standard antibiotic therapy. Thus, the growing problem of 
bacterial multi-antibiotics resistance could be suppressed 
by using carbohydrates as anti-adhesion drugs for 
infectious diseases.9 One of the best characterized 
enterobacterial surface lectins is mannose-specific type 1 
fimbriae, a common bacterial adhesin involved in receptor-
ligand interactions.10,11 In uropathogenic Escherichia coli 
(UPEC), mannose-specific adhesion is mediated by the 
FimH adhesin located at the tip of type 1 fimbriae.12,13 
Several studies were reported with a large number of -D-
mannopyranosides as high-affinity ligands for E. coli type 1 
adhesin. Recent research in this area has been focused on 
multivalent mannosides14–18 which were found to bind 
with high affinity to FimH and thus prevent agglutination of 
red blood cells mediated by cross-linking of surface 
epitopes containing mannose. However, these high 
molecular weight structures are predicted to be poorly 
permeable to the gastrointestinal tract and probably not 
suitable for oral dosing because of their large molecular 
weight and high polarity.19 X-ray studies revealed that 
UPEC lectin FimH perfectly accomodates one single  
-mannosyl residue.18–22 It was determined that the 
entrance of the binding site region of FimH is bordered with 
two aromatic residues belonging to Tyr48 and Tyr137 (so 
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of aromatic aglycon moiety induces – stacking 
interactions within the tyrosine gate enhancing the affinity 
of the relevant aromatic mannosides compared to alkyl 
mannosides.24 Aryl mannoside inhibitors of hemagglu-
tination were first reported many years ago11,25 and 
several structure-activity relationship studies followed.26–28 
Further studies also showed that elongation of aglycon 
alkyl chains of synthetic FimH mannoside antagonists is of 
importance and that it enhances their potency.21,22,24,29 
Our previous reports were focused on the exploration of 
the influence of monovalent FimH mannoside antagonists 
with structurally different aglycons (lipophilic adamantane, 
aromatic ferrocene) on the resulting binding capacities.30–32 
Aromatic ferrocene mannosides showed better inhibitory 
potency in preventing the adhesion of E. coli to 
erythrocytes.31,32 Since it is known that the potency of 
inhibition of hemagglutination can be further enhanced by 
extending the aglycon by a second aryl system26 which is 
also capable of reaching the hydrophobic rim formed by 
Tyr48, Tyr137 and Ile52, we have explored the inhibitory 
potential of -mannosides with N-aryl substituted  
3-hydroxypyridin-4-ones (N-aryl 3,4-HPs) as aglycon parts 
of a molecule.[33] 3,4-HPs possess the needed structural 
characteristics since they are hydrophobic bicyclic 
compounds composed of the 3,4-HP core with an aryl 
extension. The 3,4-HPs, a family of heterocyclic 
compounds, have been extensively studied due to their 
broad field of application. They are used for therapeutical 
purposes and diagnosis, solvent extraction, and chemical 
analysis.34–37 They also have excellent chelating properties 
toward ‘hard’ metals, such as Fe3+, and represent a very 
promising structural pattern in the design of new chelating 
drugs.34 Structural modifications of the heterocyclic ring at 
different positions including 3-hydroxyl oxygen can 
influence the various properties of 3,4-HPs.37,38 
 Previously, we have prepared and evaluated the 
mannosides I–IV (Figure 1) that contain para substituted N-
aryl 3,4-HP moieties in aglycon part.[33] Of all compounds 
we have tested so far, they have shown the greatest 
potential as FimH antagonists. Therefore, we have exten-
ded our research on novel N-aryl 3,4-HP derivatives. 
 Here we report the synthesis of meta substituted  
N-aryl 3,4-HP mannosides, their evaluation and comparison 
with previously described para derivatives. Structure-
acitivity relationship study using hemagglutination assay 
was performed in order to gain insight in structural 
patterns that influence the most binding affinities of N-aryl 
3,4-HP mannosides towards FimH adhesin. 
 
EXPERIMENTAL 
Materials and Methods 
Reagents and solvents for the synthesis of compounds 
were obtained from commercial sources (Sigma-Aldrich 
Corp. and J. T. Baker). When necessary solvents were 
further purified and/or dried using standard methods. Thin 
layer chromatography (solvents and ratios are given in the 
text) was performed on Fluka silica gel (60 F 254) plates 
(0.25 mm). Visualization was effected by use of UV light at 
254 nm (UV Lamp Type 6, neoLab), iodine and/or charring 
with sulfuric acid. Column chromatography (solvents and 
ratios are also given in the text) was performed on Merck 
silica gel 60 (size 70–230 mesh ASTM). Melting points were 
determined in open capillaries using Büchi B-540 melting 
point apparatus and are uncorrected. 1H and 13C NMR 
spectra were recorded with Bruker Avance spectrometer  
at room temperature in deuterated dimethyl sulfoxide at 
600 MHz and 150 MHz, respectively. Chemical shifts (δ) are 
given in parts per million (ppm) downfield from 
tetramethylsilane as internal standard. Electrospray 
ionization mass spectrometry (ESI-MS) was performed 
using Agilent 6410 MS instrument. High resolution mass 
spectra (HRMS) were obtained by Agilent Q-TOF iFunnel 
LC/MS instrument. 
 The purity of the final compounds (3a–3c, 92.4 %, 
93.0 % and 96.3 %, respectively based on the Area%) was 
obtained using HPLC at 254 nm. The instrument used was 
Agilent 1100 HPLC equipped with quaternary pump, 
thermostatted column compartment, an autosampler and 
DAD detector. The conditions of the analysis were as 
follows: Waters Symmetry Shield TM RP 18 column (250 mm 
 4.6 mm; 5 µm, column temperature 25 °C), 1.6 mL min–1 
flow, acetonitrile : ultra pure water = 55 : 45, v / v mobile 
phase, isocratic elution, sample concentration 2 mg mL–1, 
injection volume 7 µL. 
General Procedure for Synthesis of 
Pyridinones 1a–1c 
A mixture of 3-hydroxy-2-methyl-4-pyrone (maltol, 1 g, 
7.93 mmol), appropriate aromatic amine (7.93 mmol) and 
p-toluenesulfonic acid (0.1500 g, 0.79 mmol) in water (20 mL) 
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was heated in a sealed thick-walled glass tube for 48 h at 
150 °C. The crude product, obtained by cooling the reaction 
mixture to room temperature, was filtered off and 
recrystallized (from methanol). The purity of the products 




Yellow solid, 1.0201 g (60 %), mp 168.8–170.6 °C. 1H NMR 
δ / ppm: 1.97 (s, 3H, CH3), 2.38 (s, 3H, CH3-Ar), 6.20 (d, 1H, 
J = 7.31 Hz, H-5), 7.24 (d, 1H, J = 7.80 Hz, H-Ar), 7.27 (s, 1H, 
H-Ar), 7.35 (d, 1H, J = 7.61 Hz, H-Ar), 7.44 (t, 1H, J = 7.65 Hz, 
H-Ar), 7.53 (d, 1 H, J = 7.31 Hz, H-6). 13C NMR δ / ppm: 13.25, 
20.64, 110.71, 123.88, 127.30, 129.30, 129.61, 128.50, 





Yellow solid, 0.2399 g (13 %), mp 240.0–241.7 °C. 1H NMR 
δ / ppm: 1.99 (s, 3H, CH3), 3.81 (s, 3H, OCH3), 6.20 (d, 1H,  
J = 7.30 Hz, H-5), 6.99–7.01 (m, 1H, H-Ar), 7.06 (s, 1H, H-Ar), 
7.09–7.11 (m, 1H, H-Ar), 7.46 (t, 1H, J = 8.09 Hz, H-Ar), 7.54 
(d, 1H, J = 7.30 Hz, H-6). 13C NMR δ / ppm: 13.16, 55.47, 
110.64, 112.60, 114.91, 118.90, 130.28, 128.47, 137.69, 




Yellow solid, 0.3418 g (18 %), mp 217.9–218.7 °C. 1H NMR 
δ / ppm: 1.93 (s, 3H, CH3), 6.25 (d, 1H, J = 7.37 Hz, H-5), 7.64 
(d, 1H, J = 7.37 Hz, H-6), 7.83–7.88 (m, 1H, H-Ar), 7.98–8.00 
(m, 1H, H-Ar), 8.38-8.40 (m, 2H, 2H-Ar). 13C NMR δ / ppm: 
13.31, 111.16, 122.42, 123.43, 130.91, 133.94, 128.43, 
137.81, 142.08, 144.96, 148.16, 169.88. ESI-MS: m / z 247.2 
[M+H]+. 
General Procedure for Synthesis of 
Acetylated Mannosides 2a–2c 
Prepared pyridinones 1a–1c were dissolved in dry DCM (4 mL). 
Collidine (1.17 equiv.) and silver trifluoromethanesulfonate 
(AgOTf, 1.17 equiv.) were added next and the mixtures 
were stirred in a dry ice bath. 2',3',4',6'-Tetra-O-acetyl-1-
bromo-α-D-mannopyranose, prepared previously according 
to a known procedure[39], was dissolved in dry DCM (2 mL) 
and added gradually during 1 h to the reaction mixtures  
(2 equiv. for each reaction). After 4 h another 0.57 
equivalent of AgOTf were added and the mixtures were 
stirred for 24 h. They were monitored by TLC (ethyl acetate : 
methanol = 5 : 1, v / v), filtered over a celite bed and washed 
with DCM. Organic layers were washed first with cold 
water, then with cold 3 % aqueous HCl solution and water 
again. They were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The residues were purified by 
column chromatography on silica gel (ethyl acetate : 





Red oil, 0.1131 g (19 %). 1H NMR δ / ppm: 1.97 (s, 3H, CH3), 
1.98, 2.06, 2.10, 2.17 (s, 12H, 4 × CH3, Ac), 2.40 (s, 3H, CH3-
Ar), 4.00 (m, 1H, H-6'b), 4.15 (m, 1H, H-6'a), 4.24 (br s, 1H, 
H-5'), 5.20 (t, 1H, J = 9.82 Hz, H-4'), 5.45–5.47 (m, 2H, H-2', 
H-3'), 6.33 (s, 1H, H-1'), 7.32–7.51 (m, 6H, H-5, H-6, 4 × H-
Ar). 13C NMR δ / ppm: 14.62, 20.30, 20.33, 20.34, 20.47, 
20.62, 61.50, 65.11, 68.00, 68.31, 68.90, 94.33, 122.42, 
125.75, 129.53, 130.52, 139.71, 142.10, 144.20, 153.88, 





Colourless oil, 0.2537 g (47 %). 1H NMR δ / ppm: 1.96 (s, 3H, 
CH3), 1.98, 2.06, 2.10, 2.17 (s, 12H, 4 × CH3, Ac), 3.82 (s, 3H, 
OCH3), 4.00 (dd, 1H, J = 12.12 Hz, J = 2.10 Hz, H-6'b), 4.14 
(m, 1H, H-6'a), 4.23–4.27 (m, 1H, H-5'), 5.20 (app t, 1H, J = 
9.99 Hz, J = 9.97 Hz, H-4'), 5.38–5.45 (m, 2H, H-2', H-3'), 6.35 
(s, 1H, H-1'), 7.06–7.08 (m, 1H, H-Ar), 7.15–7.19 (m, 2H, 2 × 
H-Ar), 7.23 (d, 1H, J = 6.47 Hz, H-5), 7.34 (d, 1H, J = 6.47 Hz, 
H-6), 7.51 (t, 1H, J = 8.03 Hz, J = 7.97 Hz, H-Ar). 13C NMR δ / 
ppm: 14.53, 20.33, 20.36, 20.49, 55.61, 61.57, 65.13, 68.05, 
68.43, 68.83, 94.12, 111.14, 112.75, 115.73, 117.35, 
122.34, 130.58, 143.34, 144.21, 153.73, 158.44, 159.89, 




Yellow oil, 0.2610 g (21 %). 1H NMR δ / ppm: 1.97 (s, 3H, 
CH3), 1.98, 2.06, 2.10, 2.17 (s, 12H, 4 × CH3, Ac), 4.02 (dd, 
1H, J = 12.28 Hz, J = 2.32 Hz, H-6'b), 4.15 (m, 1 H, H-6'a), 
4.23–4.26 (m, 1H, H-5'), 5.21 (app t, 1H, J = 10.11 Hz, J = 
10.09 Hz, H-4'), 5.41–5.45 (m, 2H, H-2', H-3'), 6.37 (s, 1H, H-
1'), 7.28 (d, 1H, J = 6.46 Hz, H-5), 7.42–7.43 (m, 1H, H-6), 
7.91 (t, 1H, J = 8.13 Hz, H-Ar), 8.05–8.06 (m, 1H, H-Ar), 8.45–
8.47 (m, 1H, H-Ar), 8.49–8.50 (m, 1H, H-Ar). 13C NMR δ / 
ppm: 14.52, 20.23, 20.27, 20.39, 61.50, 65.11, 68.02, 68.35, 
68.83, 94.16, 121.13, 124.68, 131.15, 132.29, 142.52, 
144.26, 148.12, 154.19, 169.27, 169.34, 169.41, 169.73. 
ESI-MS: m / z 577.2 [M+H]+. 
General Zemplén Deacetylation 
Procedure 
Acetylated compounds 2a–2c were dissolved in dry 
methanol (2 mL). A solution of sodium methoxide in 
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mixture. Reaction mixtures were stirred at room 
temperature for 1 h and monitored by TLC (acetonitrile : 
H2O = 5 : 1, v / v). They were purified first by flash chromato-
graphy using methanol as solvent. The organic layers were 
then concentrated in vacuo. The remaining residues were 
purified by column chromatography on silica gel 
(acetonitrile : H2O : methanol = 5 : 1 : 1, v / v / v) giving 




Red oil, 0.0793 g (24 %). 1H NMR δ / ppm: 2.06 (s, 3H, CH3), 
2.40 (s, 3H, CH3-Ar), 3.43–3.62 (m, 4H, H-4', H-5', H-6'a, H-
6'b), 3.81 (dd, 1H, J = 9.02 Hz, J = 3.21 Hz, H-3'), 3.92 (s, 1H, 
H-2'), 4.53 (br s, 1H, OH), 5.18 (br s, 3H, 3 × OH), 5.75 (d, 
1H, J = 1.75 Hz, H-1'), 7.14 (d, 1H, J = 6.58 Hz, H-5), 7.20–
7.36 (m, 4H, H-6, 3 × H-Ar), 7.51 (app t, 1H, J = 7.82 Hz, J = 
7.86 Hz, H-Ar). 13C NMR δ / ppm: 14.52, 20.59, 60.92, 66.94, 
69.66, 70.46, 75.12, 98.21, 110.31, 122.48. 122.86, 125.81, 
129.43, 130.26, 139.61, 141.74, 142.40, 156.27, 158.11. 
ESI-MS: m / z 378.2 [M+H]+. HRMS: calcd. for C19H23NO7 




Yellow oil, 0.0447 g (80 %). 1H NMR δ / ppm: 2.07 (s, 3H, CH3), 
3.45–3.61 (m, 4H, H-4', H-5', H-6'a, H-6'b), 3.78 (s, 1H, H-3'), 
3.81 (s, 3H, OCH3), 3.91 (br s, 1H, H-2'), 4.54 (br s, 1H, OH), 
5.12 (br s, 3H, 3 × OH), 5.75 (s, 1H, H-1'), 7.13–7.17 (m, 4H,  
H-5, 3 × H-Ar), 7.31 (d, 1H, J = 6.51 Hz, H-6), 7.51 (app t, 1H, 
J = 8.36 Hz, J = 8.05 Hz, H-Ar). 13C NMR δ / ppm: 14.52, 55.62, 
60.93, 66.71 69.67, 70.46, 75.19, 98.30, 110.16, 111.25, 
115.63, 117.50, 123.09, 130.53, 141.75, 143.41, 156.43, 
157.93, 159.88. ESI-MS: m / z 416.2 [M+H]+. HRMS: calcd. for 




Brown oil, 0.0202 g (69 %). 1H NMR δ / ppm: 2.07 (s, 3H, 
CH3), 3.35–3.65 (m, 4H, H-4', H-5', H-6'a, H-6'b), 3.77 (dd, 1H, 
J = 9.04 Hz, J = 3.31 Hz, H-3'), 3.89–3.91 (m, 1H, H-2'), 4.54 
(br s, 1H, OH), 5.19 (br s, 2H, 2 × OH), 5.79 (s, 1H, H-1'), 7.17 
(d, 1H, J = 6.55 Hz, H-5), 7.35 (d, 1H, J = 6.55 Hz, H-6), 7.90 
(t, 1H, J = 8.16 Hz, H-Ar), 8.00–8.08 (m, 1H, H-Ar), 8.44–8.48 
(m, 2H, 2 × H-Ar). 13C NMR δ / ppm: 14.56, 62.75, 66.57, 
69.66, 70.42, 75.19, 98.22, 110.34, 121.24. 126.32, 126.61, 
127.93, 131.20, 139.61, 142.73, 148.15, 156.80, 158.22. 
ESI-MS: m / z 431.1 [M+Na]+. HRMS: calcd. for C18H20N2O9 
[M+H]+ 409.1247; found at m / z 409.1240. 
Inhibition Hemagglutination Test 
A recombinant type 1 fimbriated E. coli strain, E. coli HB 101 
(pPKl4), was used and cultured according to the protocol 
applied in our previous studies.[30–33] Guinea pig 
erythrocytes were isolated and used as described.[30,31,33] 
Mannosides 3a–3c were dissolved in distilled deionized 
water, and 10 μL of stock sugar solutions (diluted solutions 
starting from 20 mM concentration) was mixed with 10 μL 
of bacteria suspension in wells in V-shaped 96-well 
microtiter plates (Nunc). After 10 min, guinea-pig 
erythrocytes (10 μL) were added. Erythrocyte agglutination 
was read after approximately 10 min at room temperature. 
The lowest sugar concentration that inhibited hemagglu-
tination was determined visually as inhibition titer (IT). IT 
values were obtained from four independent tests. 
 
RESULTS AND DISCUSSION 
We report the synthesis of novel N-aryl 3,4-HP mannosides 
with methyl, methoxy and nitro substituents in the meta 
position of the aryl part. The aim of our work was to 
examine the inhibitory potential of prepared α-mannosides 
with the N-aryl 3,4-HP aglycon toward the adhesion of  
E. coli to erythrocytes and to study the influence of 
substituents at the m- and p-aryl position on the FimH 
affinity. Target compounds 3a–3c were prepared as shown 
in Scheme 1. 
 Novel compounds 1a–1c were prepared following 
the previously published procedure for analogous para 
derivatives.[33] Aryl parts of the pyridinones 1a–1c were 
 
 
Scheme 1. Preparation of pyridinone mannosides 3a–3c: i) autoclave, p-TsOH, H2O, 150 °C, 48 h; ii) AgOTf, collidine, 
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meta substituted phenyls: m-methylphenyl (1a), m-
methoxyphenyl (1b) and m-nitrophenyl (1c). Their 
structures were confirmed using NMR spectroscopy and 
mass spectrometry techniques. Acetylated glycoconjugates 
2a–2c were synthesized by the Königs-Knorr method[2,33] 
using acetobromomannose as the glycosyl donor and meta 
substituted N-aryl 3,4-HPs 1a–1c as acceptors in the 
presence of AgOTf. Because of participating acetyl group at 
the 2-position on the sugar molecule, Königs-Knorr reaction 
resulted with stereospecific formation of 1,2-trans 
glycosides, acetylated α-mannosides 2a–2c in 19–47 % 
yields. Compounds 2a–2c were deprotected using Zemplén 
deacetylation.[2,11] The efficacy of deacetylation was 
confirmed by the absence of the characteristic signals in 1H 
and 13C NMR spectra belonging to acetyl groups. Target α-
mannosides 3a–3c were obtained in 24–80 % yields. 
 In vitro structure-activity relationship study, using 
hemagglutination assay (HA), was performed on para[33] 
and meta substituted N-aryl 3,4-HP mannosides. These 
compounds were tested as antagonists of FimH-mediated 
bacterial adhesion. The minimal concentration of a tested 
meta substituted compound required to prevent E. coli 
FimH from agglutinating guinea pig erythrocytes was 
determined (expressed as IT value) and compared to that 
of a reference inhibitor, methyl α-D-mannoside (MeMan) 
and previously described 3,4-HP mannosides (I–IV). The 
results are shown in Figure 2. 
 All tested compounds showed better inhibitory 
potency than the reference MeMan. Determined IT values 
for compounds 3a–3c were 2.6, 3.0, 3.3 mM, respectively. 
These results show that α-mannosides 3a–3c are 6–7 times 
better inhibitors of the hemagglutination than MeMan. 
Previously described mannoside IV showed a very 
significant 32-fold improvement in potency relative to 
MeMan. Even more improved inhibitory potencies were 
also observed with mannosides that possess biaryl 
aglycons.[24,25] Furthermore, all derivatives with 
substituents in either meta or para position on the phenyl 
ring showed stronger activity compared to compound I 
with no substituents in the aryl part of the molecule, 
indicating the importance of phenyl ring substitution for 
binding capacity. Mannosides 3b and 3c, with methoxy and 
nitro substituents in meta position, respectively, showed 
higher IT value compared to corresponding para 
derivatives. This result implies that para substituent is 
relevant for the binding affinity. Based on obtained results 
and on molecular modeling study performed on para 
compounds[33] which indicated the hydrogen bond 
between p-methoxy or p-nitro moiety and hydroxyl group 
of Tyr137 residue in FimH binding pocket, one can conclude 
that displacement of the groups from para to meta position 
influences unfavorably on hydrogen bonding with Tyr137 
and consequently on effectiveness of binding to FimH. On 
the other hand, analogue 3a with methyl substituent in 
meta position showed two-times better inhibitory activity 
than mannoside II. This suggests that hydrophobic 
substituent in meta position positively affects the binding 
of 3,4-HP mannosides in FimH binding site. Obtained results 
will be considered in our future studies in the design of 
novel 3,4-HP mannosides as FimH antagonists. Preparation 
and evaluation of disubstituted N-aryl 3,4-HP derivatives 
which have alkyl substituents in meta position and such 
groups in para position which can act as hydrogen bond 
acceptors in hydrogen bond with hydroxyl group of Tyr137 
residue could be one promising route. 
 
CONCLUSION 
Novel meta substituted (methyl-, methoxy-, nitro-) N-aryl 
3-hydroxypyridin-4-one mannosides were synthesized and 
their inhibitory potencies as FimH antagonists were 
evaluated and compared to previously prepared para 
substituted 3,4-HP α-mannosides. The hemagglutination 
assays revealed greater preference of FimH towards the 
para substituted N-aryl 3,4-HP mannosides, especially 
those with -OCH3 and -NO2 substituents. This study 
provides guidelines for rational design of novel, more 
effective FimH antagonists. In the continuation of our 
research on 3,4-HP derived FimH antagonists we plan 
further chemical transformations on aryl moiety. Based on 
obtained results, we conclude that the most promising 
route for the preparation of more efficient 3,4-HP derived 
E. coli anti-adhesives is introduction of alkyl substituents in 
meta position and substituents which can form hydrogen 




Figure 2. Comparison of IT values of N-aryl 3,4-HP 
mannosides 3a-3c towards type 1 fimbriated E. coli. The 
minimal concentration of a compound required to inhibit 
hemagglutination (IT value) was obtained from four 
independent tests for m-substituted compounds; 3a 2.6 mM, 
3b 3.0 mM, 3c 3.3 mM and compared with p-substituted 
compounds; I 10 mM, II 5 mM, III 2.5 mM, IV 0.6 mM. Methyl 
α-D-mannopyranoside (MeMan) is used as reference inhibitor 
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